JP2007215546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007215546A5 JP2007215546A5 JP2007076890A JP2007076890A JP2007215546A5 JP 2007215546 A5 JP2007215546 A5 JP 2007215546A5 JP 2007076890 A JP2007076890 A JP 2007076890A JP 2007076890 A JP2007076890 A JP 2007076890A JP 2007215546 A5 JP2007215546 A5 JP 2007215546A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fusion protein
- amino acid
- uti
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 22
- 102000037865 fusion proteins Human genes 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 230000002401 inhibitory effect Effects 0.000 claims 12
- 108091005804 Peptidases Proteins 0.000 claims 10
- 239000004365 Protease Substances 0.000 claims 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims 5
- 102220389089 c.33G>T Human genes 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 102220228148 rs1064793325 Human genes 0.000 claims 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000002158 endotoxin Substances 0.000 claims 4
- 238000003780 insertion Methods 0.000 claims 4
- 230000037431 insertion Effects 0.000 claims 4
- 230000017306 interleukin-6 production Effects 0.000 claims 4
- 238000007792 addition Methods 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000046699 human CD14 Human genes 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 230000006229 amino acid addition Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000002849 elastaseinhibitory effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102200025791 rs179363876 Human genes 0.000 claims 1
- 102220234443 rs398123324 Human genes 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000006433 tumor necrosis factor production Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007076890A JP4891125B2 (ja) | 2005-06-03 | 2007-03-23 | 抗cd14抗体融合蛋白質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005164901 | 2005-06-03 | ||
| JP2005164901 | 2005-06-03 | ||
| JP2007076890A JP4891125B2 (ja) | 2005-06-03 | 2007-03-23 | 抗cd14抗体融合蛋白質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551131A Division JP4067557B2 (ja) | 2005-06-03 | 2006-06-05 | 抗cd14抗体融合蛋白質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007215546A JP2007215546A (ja) | 2007-08-30 |
| JP2007215546A5 true JP2007215546A5 (https=) | 2009-07-16 |
| JP4891125B2 JP4891125B2 (ja) | 2012-03-07 |
Family
ID=38493452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007076890A Expired - Fee Related JP4891125B2 (ja) | 2005-06-03 | 2007-03-23 | 抗cd14抗体融合蛋白質 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4891125B2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3628731B1 (en) | 2014-02-26 | 2021-04-21 | Mochida Pharmaceutical Co., Ltd. | Novel anti-presepsin antibody |
-
2007
- 2007-03-23 JP JP2007076890A patent/JP4891125B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013502458A5 (https=) | ||
| JP2014518883A5 (https=) | ||
| JP2007045828A5 (https=) | ||
| JP2010504336A5 (https=) | ||
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| DE60031792D1 (de) | Schimärische amyloid-beta peptide | |
| JP2012525836A5 (https=) | ||
| JP2008515446A5 (https=) | ||
| JP2008508859A5 (https=) | ||
| JP2014224134A5 (https=) | ||
| JP2005120106A5 (https=) | ||
| HRP20100115T1 (hr) | Protutijela protiv peptida amiloid-beta | |
| RU2010151725A (ru) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их | |
| JP2013520487A5 (https=) | ||
| TW200616657A (en) | Therapeutic peptides and method | |
| ES2641373T3 (es) | Uso de P3 de proteínas de fusión de bacteriófagos como agentes de unión amiloides | |
| JP2002532561A5 (https=) | ||
| JP2014521313A5 (https=) | ||
| KR20180083382A (ko) | 개선된 tnf 결합제 | |
| IL303152A (en) | Compositions and methods for selective depletion of target molecules | |
| JP2019535321A5 (https=) | ||
| JP2020517643A5 (https=) | ||
| US5514653A (en) | Method of blocking the SEC receptor | |
| JP2007215546A5 (https=) | ||
| Argilés et al. | Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits |